Research and Industry Collaboration Opportunities

Enterprise Innovation brings internal and external collaboration opportunities to our faculty and trainees. These programs provide extra funding and opportunities to work with industry to advance faculty/trainees' translational research projects. 

Please contact Dr. James Bellush at if you have any questions or need guidance on your application.

1. BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18, no clinical trial)

  • Application Deadline: May 29, 2024
  • Award Details: Up to $750k per year, 3 year maximum
  • Funding opportunity for research which aims to translate novel recording and modulation technologies that could be used to treat and/or diagnose CNS diseases
  • Eligible projects include proof of concept stage through FIH clinical readiness.  Devices may incorporate any signal modality (electrical, optical, magnetic, acoustic)
  • Plan for Enhancing Diverse Perspectives will be required for application

2. BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3, clinical trial optional)

  • Application Deadline: May 29, 2024
  • Award Details: Up to $500k per year in UG3 phase, up to $1.5M per year in UH3 phase
  • Funding opportunity for neuroscience projects with transdisciplinary, collaborative researchers in fields of computational biology, physics, engineering, and data sciences; encourages participation of early-mid career investigators from diverse, under-represented backgrounds
  • Opportunity aims to encourage applicants to pursue milestone-driven translational and clinical projects for recording and/or stimulating devices to treat CNS disorders
  • Award will support regulatory activities needed for IND enabling work and subsequently FIH or early stage clinical study

3. Rising Star Awards: One Mind Institute

  • Eligibility: Early-career investigators in psychiatry (must be within 6 yrs of initial academic appointment) aiming to gain deeper mechanistic understanding of psychiatric disorders and therapeutic action
    • Primary goal is to identify / develop biomarkers and therapeutic interventions to better diagnose, treat, and prevent debilitating psychiatric disorders
    • Proposals may span basic, preclinical, translational, and clinical research
    • Indications of interest include (but not limited to): schizophrenia, bipolar disorder, depression, obsessive-compulsive disorder, eating disorders, PTSD, anxiety disorders, suicidality
  • Funding Duration: 3 years
  • Funding Amount: $300k total
  • Application Deadline: June 6, 2024

4. Michelson Prize: Human Immunome Project

  • Eligibility: Early-career investigators (<35 yrs age, can be PhD student, post-doc, PI) conducting research in the fields of human immunology, vaccine discovery, or immunotherapy to address diseases with a global impact.
    • Cross-discipline approaches (biochemistry, molecular biology, protein engineering, AI / ML, biophysics, nanotechnology) aiming to characterize immune system function, vaccine strategies, and innovations in immunotherapy are prioritized
  • Funding Duration: 1 year
  • Funding Amount: $150k
  • Application Deadline: June 9, 2024

5. Simons Foundation: Autism Research Initiative – Pilot Award

  • Eligibility: Early-career or established investigators aiming to pursue exploratory, high risk research ideas to test novel hypotheses in the autism field.
    • Applications within scope for this award should focus on research that:
      • Characterizes genetic or environmental ASD risk factors
      • Links genetic risk factors to molecular / cellular biomarkers of ASD
      • Explores how ASD related changes in neural circuitry affect behavioral mechanisms
      • Informs the screening and development of novel therapeutic interventions for humans
  • Funding Duration: 2 years
  • Funding Amount: $500k total (including 20% indirect costs)
  • Application Deadline: June 13, 2024

6. Mission BioCapital 2024 Platinum Program

  • Eligibility: Mission BioCapital is an early-stage biotech fund with a strong preference for novel therapeutics that opportunistically invests in adjacencies including medtech and diagnostics. They are disease- and modality-agnostic. They are looking for a team with at least 1 full-time dedicated person who will be advancing the science in their affiliated labs and responsible for developing the fundraising strategy and business model. In some situations, there are several people already a part of the company who divide these responsibilities among themselves. Mission BioCapital is happy to discuss further as well. 
  • Platinum Program will award up to six winning startup-ups with:
    • A guaranteed lab bench in one of Mission BioCapital’s affiliated incubators located in 13 cities in the U.S. and Europe
    • Up to $500,000 of seed capital per awardee
    • Drug discovery services from Alloy Therapeutics to enable companies with a de-risked pathway to lead candidate
    • Strategic scientific and business development mentorship from experts across Mission BioCapital’s corporate network, including sponsors Mission BioCapital, Lilly, OVI, and Alloy Therapeutics
  • Final Deadline for Application Submission: July 15, 2024

Applicants that will move on as a finalist will receive information about the process in August 2024. All final decisions will be communicated by the end of September 2024. 

7. Parkinson’s Disease Translational Research Program: SPARK NS

Eligibility: Academic principal investigators in US, UK, or Canada with a translational research focus on Parkinson’s Disease, spanning any development stage from target identification/validation to clinical trials.

Applications will be evaluated on the following criteria:

  • Addressing an unmet clinical need in Parkinson’s disease
  • Using a novel, robust mechanism or approach
  • High probability of success at accomplishing proposed translational objectives

Funding Duration: 2 years

Funding Amount: Milestone based support up to $2,000,000 per project during two-year program, including discretionary PI funding of $50,000 per year.

SPARK NS also provides education, mentorship, and networking opportunities focused on drug development and innovation.

Application Deadline: Portal will open for submissions on May 31, 2024 and close on July 26, 2024.  Optional pre-submission review period will remain open until June 28, 2024.

Please see attached PDF icon RFP document for further information.

8. Empire State Development Innovation Matching Grants Program

Objective: Empire State Development’s Division of Science, Technology, and Innovation (“NYSTAR”), Innovation Matching Grants Program (the “IMG Program”) aims to grow small businesses and support the development of new technologies in New York State by providing matching funds for federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants.

Eligibility Guidelines:

  • Businesses that are: resident in New York State; independently owned and operated, not dominant in their field; and employing 100 or less persons.
  • Actively in the process of applying for a Phase I or Phase II SBIR or STTR award from a participating federal agency or have received an SBIR/STTR award within 12 months of the announcement of the specified round.
  • Currently operate their business in New York.

* Grant recipients must remain headquartered and operate or manufacture in New York State for at least two years following the successful commercialization of the IMG Program grant recipient’s product or products.

Award and Application Information:

The Matching Grants Program will match: 

  • The award for Phase I applicants, not to exceed $100,000. 
  • The award for Phase II applicants, not to exceed $200,000. 
  • Technical assistance resources for Phase II and Phase III awards. 

In no event, shall the funding provided from the IMG Program exceed 50% of the federal award.

Round 1 of funding is open now and accepting applications until July 31, 2024, or until all the allocated funds are committed. Learn more about the program and read the program guidelines here before applying.

9. Sanofi iAwards North America 2024 – 2025

Objective: Translational research award seeks to convert promising early stage, disease relevant projects into sponsored research programs and subsequently licensing / start-up opportunities within the Sanofi early stage pipeline

Eligibility Guidelines: 

  • Pre-proposals must be non-confidential
  • Must not include 3rd party collaborators (academic partners permitted)
  • Must outline research milestones and work-plan achievable in 12 mos
  • Learn more about the therapeutic areas of interest and view detailed timeline for submissionFile here. A pre-proposal template is available File here

*CTL office must validate the application prior to submission

    • Please provide CTL contact email in “General Information”:
    • James Bellush, Manager, Scientific Scouting
    • Email:

Award and Application Information:

  • $150,000 for 12 months (direct + indirect costs included)
  • Additional R&D support and guidance included from Sanofi
  • After CTL review is complete, pre-proposal submitted through this link
  • Pre-proposals must be submitted to Sanofi by June 3, 2024
  • Submission of completed Full Proposals to Sanofi by Institutions by September 2,  2024